| Aug 8 |
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 8 |
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 1 |
Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
|
| Jun 25 |
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
|
| Jun 1 |
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
|
| May 30 |
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
|
| May 24 |
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
|
| May 23 |
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
|
